What is the appropriate management of hyperkalemia?

Management of Hyperkalemia

The appropriate management of hyperkalemia requires a dual approach: immediate stabilization based on severity and ECG changes, followed by long-term prevention strategies that prioritize maintaining life-saving therapies like RAASi rather than discontinuing them. 1

Acute Management Algorithm

Immediate Assessment

• Check ECG and potassium level simultaneously - ECG changes and K+ ≥6.5 mEq/L mandate urgent intervention 1
• Verify true hyperkalemia (exclude pseudohyperkalemia from hemolysis, fist clenching, or poor phlebotomy technique) 1

Acute Treatment Sequence

For severe hyperkalemia (K+ ≥6.5 mEq/L) or any ECG changes:

1. IV Calcium (10 mL of 10% calcium gluconate or chloride) - First-line cardiac membrane stabilization, acts within 1-3 minutes 1, 2

2. Shift potassium intracellularly (within 30-60 minutes):

   • IV insulin/glucose (10 units regular insulin + 50 mL dextrose) - cornerstone therapy but carries significant hypoglycemia risk, especially in non-diabetics with low baseline glucose 1, 2
   • Nebulized salbutamol (20 mg in 4 mL) - provides synergistic effect with insulin and is recommended in combination 1, 2
   • Note: β-agonists have short duration (2-4 hours) 1

3. Sodium bicarbonate IV - ONLY in patients with concurrent metabolic acidosis 1

4. Enhance elimination:

   • Diuretics - in hypervolemic, non-oliguric patients with preserved kidney function 1
   • Hemodialysis - for oliguria, ESRD, or refractory cases 1

Critical Pitfall: Insulin-glucose therapy carries considerable hypoglycemia risk, particularly in non-diabetic patients with low baseline glucose - close monitoring is essential 2

Chronic/Recurrent Hyperkalemia Management

Primary Principle

The initial aim should be to normalize serum potassium and correct reversible precipitating factors 3. However, the most recent 2025 European guidance emphasizes that reducing recurrence risk should be standard practice regardless of setting 3.

Management Strategy

1. Identify and address reversible factors:

   • Review medications (NSAIDs, potassium supplements, salt substitutes)
   • Assess for volume depletion, metabolic acidosis, or acute illness
   • Evaluate dietary potassium intake 3, 1

2. DO NOT discontinue RAASi therapy - This is a critical error that increases mortality and cardiovascular events 1, 4

   • Discontinuation of RAASi in patients with eGFR <30 mL/min/1.73m² was associated with higher mortality and major adverse cardiovascular events compared to continuation 1
   • Only 51.5% of eligible patients with CKD/HF receive RAASi despite clear indications, representing a major treatment gap 5

3. Potassium binders for long-term management:

   • Newer agents (sodium zirconium cyclosilicate or patiromer) are preferred to enable RAASi optimization 3, 4, 6
   • Sodium polystyrene sulfonate is NO LONGER recommended due to questionable efficacy and gastrointestinal adverse events 2
   • Unless the cause can be reversed, treatment is likely indefinite 3

4. After normalization with potassium binders, additional monitoring beyond routine comorbidity monitoring is not necessary 3

Monitoring Protocol

• Measure K+ within 7-10 days after starting or increasing RAASi doses 1
• Individualize monitoring frequency based on comorbidities (CKD stage, diabetes, HF, hyperkalemia history) 1
• Repetitive measurements help distinguish chronic from transient hyperkalemia 1

Key Clinical Thresholds

• Hyperkalemia definition: K+ >5.0 mEq/L (recurrent = >1 episode per year) 3
• Widely accepted threshold: K+ ≥5.5 mEq/L 1
• Adverse outcomes occur even at 5.1-5.4 mEq/L in patients with cardiorenal disease 3, 1
• Focus on clinical impact and rapid fluctuations rather than rigid thresholds 1

Critical Evidence Gaps

Current practice shows conservative management dominates (80.9% receive only monitoring, low-K+ diet, or no treatment), with only 10.8% receiving potassium binders 7. This represents inconsistent guideline implementation. Hyperkalemia recurrence remains common (28-34% at 12 months) 5, 7, highlighting the need for more aggressive prevention strategies using newer potassium binders to maintain guideline-directed RAASi therapy 3, 4.

The paradigm has shifted: treat hyperkalemia aggressively to maintain life-saving RAASi therapy rather than discontinuing RAASi to avoid hyperkalemia 3, 1, 4.